menu
    • menu
    [{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"AUTO3","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Autolus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"AUTO1","moa":"T lymphocyte","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Autolus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"AUTO3","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Autolus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"AUTO1","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Autolus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"AUTO3","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Autolus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"AUTO1","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Autolus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Obecabtagene Autoleucel","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Autolus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2021","type":"Licensing Agreement","leadProduct":"mRNA-4157","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Autolus Therapeutics \/ Moderna","highestDevelopmentStatusID":"6","companyTruncated":"Autolus Therapeutics \/ Moderna"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Acquisition","leadProduct":"Obecabtagene Autoleucel","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0.25,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.25,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Autolus Therapeutics \/ Blackstone Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Autolus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Autolus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"AUTO4","moa":"TRBC1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Autolus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Agreement","leadProduct":"CAR-T Cell Therapy","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Autolus Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"1","companyTruncated":"Autolus Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"mRNA-based Therapeutic","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Autolus Therapeutics \/ Moderna","highestDevelopmentStatusID":"1","companyTruncated":"Autolus Therapeutics \/ Moderna"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Public Offering","leadProduct":"Obecabtagene Autoleucel","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.14999999999999999,"dosageForm":"Infusion","sponsorNew":"Autolus Therapeutics \/ Jefferies","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Autolus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Autolus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"BNT211","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0.25,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.25,"dosageForm":"Infusion","sponsorNew":"Autolus Therapeutics \/ BioNTech","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ BioNTech"}]

    Find Clinical Drug Pipeline Developments & Deals by Autolus Therapeutics

    Menu

    Autolus Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Autolus Therapeutics

                            United Kingdom arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Autolus Therapeutics

                            United Kingdom arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BNT211,CARVac

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : BioNTech

                            Deal Size : $250.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            BioNTech and Autolus Collaborate To Advance CAR-T Cell Therapy Pipeline

                            Details : The collaboration will support Autolus in developing BNT211 (CLDN6 CAR-T) for treating relapsed or refractory advanced solid tumors, including ovarian cancer and sarcoma.

                            Brand Name : BNT211

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : $50.0 million

                            February 08, 2024

                            Lead Product(s) : BNT211,CARVac

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : BioNTech

                            Deal Size : $250.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Autolus Therapeutics

                            United Kingdom arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Autolus Therapeutics

                            United Kingdom arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Obecabtagene Autoleucel,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Autolus Announces Acceptance of BLA for Obe-Cel in B-cell ALL Treatment

                            Details : AUTO1 (obecabtagene autoleucel) is a CD19 CAR T cell investigational therapy. It is being evaluated in phase 1/2 clinical trials for relapsed/refractory adult B-cell Acute Lymphoblastic Leukemia.

                            Brand Name : AUTO1

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            January 22, 2024

                            Lead Product(s) : Obecabtagene Autoleucel,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Autolus Therapeutics

                            United Kingdom arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Autolus Therapeutics

                            United Kingdom arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Obecabtagene Autoleucel

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Jefferies

                            Deal Size : $150.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Autolus Announces Pricing of Public Offering

                            Details : AUTO1 (obecabtagene autoleucel) is an autologous CD19 CAR T cell therapy with a unique CD19 CAR. The CAR is designed to have a fast-off kinetic which mimics physiological T-cell receptor interactions.

                            Brand Name : AUTO1

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            December 08, 2022

                            Lead Product(s) : Obecabtagene Autoleucel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Jefferies

                            Deal Size : $150.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Autolus Therapeutics

                            United Kingdom arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Autolus Therapeutics

                            United Kingdom arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Obecabtagene Autoleucel,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Autolus Therapeutics Announces Pivotal Phase 2 FELIX Clinical Trial Has Met Primary Endpoint at Interim Analys...

                            Details : Obe-cel (AUTO1), is a CD19 CAR T cell investigational therapy designed to overcome the limitations in clinical activity and safety compared to current CD19 CAR T cell therapies.

                            Brand Name : AUTO1

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            December 08, 2022

                            Lead Product(s) : Obecabtagene Autoleucel,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Autolus Therapeutics

                            United Kingdom arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Autolus Therapeutics

                            United Kingdom arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : mRNA-based Therapeutic

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Moderna Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Moderna Exercises Option To License Proprietary Targeting Technology From Autolus

                            Details : This follows an original agreement with Moderna, granting Moderna an exclusive option to license Autolus’ proprietary binders for up to four immuno-oncology targets for incorporation in certain mRNA therapeutics.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 12, 2022

                            Lead Product(s) : mRNA-based Therapeutic

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Moderna Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Autolus Therapeutics

                            United Kingdom arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Autolus Therapeutics

                            United Kingdom arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CAR-T Cell Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Bristol Myers Squibb

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Autolus Therapeutics Announces Collaboration with Bristol Myers Squibb for Use of Autolus’ Proprietary Safet...

                            Details : Under the terms of the agreement, Autolus will receive payment for access to the RQR8 safety switch for the initial set of cell therapy programs with the potential for near term option exercise fees and development milestone payments.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            October 04, 2022

                            Lead Product(s) : CAR-T Cell Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Bristol Myers Squibb

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Autolus Therapeutics

                            United Kingdom arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Autolus Therapeutics

                            United Kingdom arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AUTO4,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Autolus Therapeutics to Present Four Clinical Data Updates at the European Hematology Association Congress

                            Details : AUTO4 is a programmed T cell product candidate in clinical development for T cell lymphoma, a setting where there are currently no approved programmed T cell therapies.

                            Brand Name : AUTO4

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            May 12, 2022

                            Lead Product(s) : AUTO4,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Autolus Therapeutics

                            United Kingdom arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Autolus Therapeutics

                            United Kingdom arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Obecabtagene Autoleucel,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA Grants Regenerative Medicine Advanced Therapy (RMAT) designation to Autolus’ CAR T cell therapy, obe-cel...

                            Details : Obecabatagene autoleucel, a CD19-directed autologous CAR-T therapy, reduce toxicity and be less prone to T cell exhaustion, which could enhance persistence and improve ability of programmed T cells to engage in serial killing of target cancer cells.

                            Brand Name : AUTO1

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            April 25, 2022

                            Lead Product(s) : Obecabtagene Autoleucel,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Autolus Therapeutics

                            United Kingdom arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Autolus Therapeutics

                            United Kingdom arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Obecabtagene Autoleucel,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Autolus Therapeutics Receives EMA Orphan Medical Product Designation for obe-cel for Treatment of Acute Lympho...

                            Details : Obe-cel is a CD19 CAR T cell investigational therapy designed to overcome the limitations in clinical activity and safety compared to current CD19 CAR T cell therapies. Obe-cel is currently being evaluated in a Phase 1 clinical trials for B-NHL.

                            Brand Name : Obe-cel

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            March 31, 2022

                            Lead Product(s) : Obecabtagene Autoleucel,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Autolus Therapeutics

                            United Kingdom arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Autolus Therapeutics

                            United Kingdom arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Obecabtagene Autoleucel

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Blackstone Life Sciences

                            Deal Size : $250.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Blackstone Life Sciences to Invest up to $250 Million in Autolus Therapeutics to Develop Obe-cel in Adult Acut...

                            Details : Obecabtagene Autoleucel (Obe-cel) is a CD19 CAR T cell investigational therapy designed to overcome the limitations in clinical activity and safety compared to current CD19 CAR T cell therapies used in adult ALL and B-NHL.

                            Brand Name : Obe-cel

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            November 08, 2021

                            Lead Product(s) : Obecabtagene Autoleucel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Blackstone Life Sciences

                            Deal Size : $250.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth